GlassScriptPhysician profile
Bennett D Schalet
NPI 1437159902
$7,758.66
in general payments reported to CMS, 2019-2025
34 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,672 · 2020: $431 · 2021: $1,053 · 2022: $1,022 · 2023: $837 · 2024: $1,093 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.33 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,769.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,058.49 | 2019-2025 | |
| Amgen INC. | $726.13 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $562.08 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $430.73 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $371.52 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $351.15 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $331.39 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $264.83 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $219.29 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $199.01 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $194.33 | 2019-2024 | Farxiga, Wainua |
| Pfizer INC. | $174.39 | 2019-2025 | |
| Novo Nordisk INC | $164.76 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $156.04 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.22 | 2019-2025 | Lifevest |
| Abbott Laboratories | $97.54 | 2019-2023 | Nc Trek Neo |
| Arbor Pharmaceuticals, INC. | $68.41 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $55.07 | 2024 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $53.35 | 2019-2022 | |
| Althera Pharmaceuticals LLC | $48.02 | 2021-2022 | |
| Boston Scientific Corporation | $46.11 | 2022-2023 | Watchman |
| Cardiovascular Systems INC. | $45.06 | 2019-2021 | |
| Irhythm Technologies, INC. | $38.34 | 2024 | Zio Monitor, Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $33.78 | 2024 | |
| Atricure, INC. | $33.46 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $30.23 | 2024 | Arcalyst |
| Philips North America LLC | $29.59 | 2024 | (5044) Mcot |
| Medicure Pharma INC. | $21.95 | 2025 | Zypitamag |
| Opsens INC. | $19.94 | 2021 | |
| Kestra Medical Technology Services, INC. | $15.54 | 2024 | Assure Wcd |
| Lilly USA, LLC | $14.85 | 2020 | |
| Amryt Pharma Holdings LTD | $14.78 | 2021 | |
| Baxter Healthcare | $13.01 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bennett Schalet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.